Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Prevalence of severe fatigue among adults with cystic fibrosis: A single center study.

Nap-van der Vlist MM, Burghard M, Hulzebos HJ, Doeleman WR, Heijerman HGM, van der Ent CK, Nijhof SL.

J Cyst Fibros. 2018 May;17(3):368-374. doi: 10.1016/j.jcf.2018.03.003. Epub 2018 Mar 29.

PMID:
29606526
2.

ECFS best practice guidelines: the 2018 revision.

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P.

J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. Review.

3.

Specific airway resistance is a better outcome parameter in bronchial provocation testing compared to FEV1 in patients with bronchial asthma.

van Nederveen-Bendien SA, Vahl J, Heijerman HGM.

J Asthma. 2018 Jan 17:1-5. doi: 10.1080/02770903.2017.1414238. [Epub ahead of print]

PMID:
29341788
4.

The optimal approach to nutrition and cystic fibrosis: latest evidence and recommendations.

Hollander FM, de Roos NM, Heijerman HGM.

Curr Opin Pulm Med. 2017 Nov;23(6):556-561. doi: 10.1097/MCP.0000000000000430. Review.

PMID:
28991007
5.

Body Weight and Body Mass Index in Patients with End-Stage Cystic Fibrosis Stabilize After the Start of Enteral Tube Feeding.

Hollander FM, de Roos NM, Belle van Meerkerk G, Teding van Berkhout F, Heijerman HGM, van de Graaf EA.

J Acad Nutr Diet. 2017 Nov;117(11):1808-1815. doi: 10.1016/j.jand.2017.07.006. Epub 2017 Sep 12.

PMID:
28919081
6.

β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.

Vijftigschild LA, Berkers G, Dekkers JF, Zomer-van Ommen DD, Matthes E, Kruisselbrink E, Vonk A, Hensen CE, Heida-Michel S, Geerdink M, Janssens HM, van de Graaf EA, Bronsveld I, de Winter-de Groot KM, Majoor CJ, Heijerman HG, de Jonge HR, Hanrahan JW, van der Ent CK, Beekman JM.

Eur Respir J. 2016 Sep;48(3):768-79. doi: 10.1183/13993003.01661-2015. Epub 2016 Jul 28.

7.

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.

Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM.

Sci Transl Med. 2016 Jun 22;8(344):344ra84. doi: 10.1126/scitranslmed.aad8278.

PMID:
27334259
8.

CT-abnormalities, bacteriology and symptoms of sinonasal disease in children with Cystic Fibrosis.

Berkhout MC, Klerx-Melis F, Fokkens WJ, Nuijsink M, van Aalderen WM, Heijerman HG.

J Cyst Fibros. 2016 Nov;15(6):816-824. doi: 10.1016/j.jcf.2016.03.004. Epub 2016 Apr 3.

PMID:
27049043
9.

Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.

van Velzen AJ, Bos AC, Touw DJ, Tiddens HA, Heijerman HG, Janssens HM.

J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):273-80. doi: 10.1089/jamp.2015.1259. Epub 2015 Dec 30.

PMID:
26716357
10.

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.

Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, Blasi F.

Eur Respir J. 2016 Feb;47(2):420-8. doi: 10.1183/13993003.00592-2015. Epub 2015 Oct 9.

11.

The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis.

van Velzen AJ, Uges JW, Le Brun PP, Shahbabai P, Touw DJ, Heijerman HG.

J Cyst Fibros. 2015 Nov;14(6):748-54. doi: 10.1016/j.jcf.2015.01.002. Epub 2015 Jan 27.

12.

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N.

Vreede CL, Berkhout MC, Sprij AJ, Fokkens WJ, Heijerman HG.

J Cyst Fibros. 2015 May;14(3):412-3. doi: 10.1016/j.jcf.2014.07.013. Epub 2014 Aug 26.

13.

Systemic absorption of nasally administered tobramycin and colistin in patients with cystic fibrosis.

Berkhout MC, van Velzen AJ, Touw DJ, de Kok BM, Fokkens WJ, Heijerman HG.

J Antimicrob Chemother. 2014 Nov;69(11):3112-5. doi: 10.1093/jac/dku239. Epub 2014 Jul 11.

PMID:
25016384
14.

Temporal bone pneumatization in cystic fibrosis: a correlation with genotype?

Berkhout MC, van Rooden CJ, Aalbers RC, el Bouazzaoui LH, Fokkens WJ, Rijntjes E, Heijerman HG.

Laryngoscope. 2014 Jul;124(7):1682-6. doi: 10.1002/lary.24575. Epub 2014 Feb 6.

PMID:
24374715
15.

Sinonasal manifestations of cystic fibrosis: a correlation between genotype and phenotype?

Berkhout MC, van Rooden CJ, Rijntjes E, Fokkens WJ, el Bouazzaoui LH, Heijerman HG.

J Cyst Fibros. 2014 Jul;13(4):442-8. doi: 10.1016/j.jcf.2013.10.011. Epub 2013 Nov 5.

16.

Importance of bacteriology in upper airways of patients with Cystic Fibrosis.

Berkhout MC, Rijntjes E, El Bouazzaoui LH, Fokkens WJ, Brimicombe RW, Heijerman HG.

J Cyst Fibros. 2013 Sep;12(5):525-9. doi: 10.1016/j.jcf.2013.01.002. Epub 2013 Jan 26.

17.

Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects.

Wilms EB, Touw DJ, Heijerman HG, van der Ent CK.

Pediatr Pulmonol. 2012 Jul;47(7):658-65. doi: 10.1002/ppul.21620. Epub 2012 Jan 3. Review.

PMID:
22684985
18.

Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case-control study.

Verregghen M, Heijerman HG, Reijers M, van Ingen J, van der Ent CK.

J Cyst Fibros. 2012 Jul;11(4):340-3. doi: 10.1016/j.jcf.2012.01.006. Epub 2012 Feb 18.

19.

Clinical impact of a highly prevalent Pseudomonas aeruginosa clone in Dutch cystic fibrosis patients.

de Vrankrijker AM, Brimicombe RW, Wolfs TF, Heijerman HG, van Mansfeld R, van Berkhout FT, Willems RJ, Bonten MJ, van der Ent CK.

Clin Microbiol Infect. 2011 Mar;17(3):382-5. doi: 10.1111/j.1469-0691.2010.03295.x. Epub 2010 Aug 30.

20.

Long-term effects of birth order and age at diagnosis in cystic fibrosis: a sibling cohort study.

Slieker MG, van den Berg JM, Kouwenberg J, van Berkhout FT, Heijerman HG, van der Ent CK.

Pediatr Pulmonol. 2010 Jun;45(6):601-7. doi: 10.1002/ppul.21227.

PMID:
20503286
21.

A productive cough.

Schild D, Heijerman HG, Sleeboom HP.

Neth J Med. 2009 Apr;67(4):154-5. No abstract available.

22.

No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.

Scheenstra RJ, Heijerman HG, Zuur CL, Touw DJ, Rijntjes E.

Acta Otolaryngol. 2010 Feb;130(2):253-8. doi: 10.3109/00016480903015150.

PMID:
19479457
23.

Demographics of glucose metabolism in cystic fibrosis.

van den Berg JM, Kouwenberg JM, Heijerman HG.

J Cyst Fibros. 2009 Jul;8(4):276-9. doi: 10.1016/j.jcf.2009.04.010. Epub 2009 May 24.

24.

Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.

Rottier BL, van Erp CJ, Sluyter TS, Heijerman HG, Frijlink HW, Boer AH.

J Aerosol Med Pulm Drug Deliv. 2009 Sep;22(3):263-9. doi: 10.1089/jamp.2008.0712.

PMID:
19466906
25.

Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.

Westerman EM, Boer AH, Touw DJ, Brun PP, Roldaan AC, Frijlink HW, Heijerman HG.

J Aerosol Med Pulm Drug Deliv. 2008 Sep;21(3):269-80. doi: 10.1089/jamp.2007.0674.

PMID:
18759658
26.

Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD).

van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG.

J Cyst Fibros. 2008 Nov;7(6):515-9. doi: 10.1016/j.jcf.2008.05.008. Epub 2008 Jul 11.

27.

Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients.

Scheenstra RJ, Rijntjes E, Tavy DL, Kingma H, Heijerman HG.

Acta Otolaryngol. 2009 Jan;129(1):4-7. doi: 10.1080/00016480801968534.

PMID:
18607923
28.

CFTR mutations in Turkish and North African cystic fibrosis patients in Europe: implications for screening.

Lakeman P, Gille JJ, Dankert-Roelse JE, Heijerman HG, Munck A, Iron A, Grasemann H, Schuster A, Cornel MC, Ten Kate LP.

Genet Test. 2008 Mar;12(1):25-35. doi: 10.1089/gte.2007.0046.

PMID:
18373402
29.

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients.

Wilms EB, Touw DJ, Heijerman HG.

J Cyst Fibros. 2008 Jan;7(1):79-84. Epub 2007 Jun 27.

30.

Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.

Vinks AA, van Rossem RN, Mathôt RA, Heijerman HG, Mouton JW.

Antimicrob Agents Chemother. 2007 Sep;51(9):3049-55. Epub 2007 Jun 18.

31.

Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in The Netherlands.

Brimicombe RW, Dijkshoorn L, van der Reijden TJ, Kardoes I, Pitt TL, van den Broek PJ, Heijerman HG.

J Cyst Fibros. 2008 Jan;7(1):30-6. Epub 2007 May 25.

32.

Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.

Westerman EM, Heijerman HG, Frijlink HW.

Expert Opin Drug Deliv. 2007 Mar;4(2):91-4.

PMID:
17335406
33.

Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.

Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, Heijerman HG.

J Cyst Fibros. 2007 Jul;6(4):284-92. Epub 2006 Dec 20.

34.

Dry powder inhalation of colistin sulphomethate in healthy volunteers: A pilot study.

Westerman EM, de Boer AH, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG.

Int J Pharm. 2007 Apr 20;335(1-2):41-5. Epub 2006 Nov 11.

PMID:
17178200
35.

Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.

de Boer AH, Hagedoorn P, Westerman EM, Le Brun PP, Heijerman HG, Frijlink HW.

Eur J Pharm Sci. 2006 Jun;28(3):171-8. Epub 2006 Mar 8.

PMID:
16650739
37.

Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis.

Slieker MG, van Gestel JP, Heijerman HG, Tramper-Stranders GA, van Berkhout FT, van der Ent CK, Jansen NJ.

Intensive Care Med. 2006 May;32(5):754-8. Epub 2006 Mar 2.

PMID:
16518642
38.

The Journal of Cystic Fibrosis: a success story.

Heijerman HG.

J Cyst Fibros. 2006 Jan;5(1):1. No abstract available.

39.

Birth prevalence and survival in cystic fibrosis: a national cohort study in the Netherlands.

Slieker MG, Uiterwaal CS, Sinaasappel M, Heijerman HG, van der Laag J, van der Ent CK.

Chest. 2005 Oct;128(4):2309-15.

PMID:
16236889
40.

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study.

Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG.

J Cyst Fibros. 2004 Mar;3(1):23-8.

41.

Nutrition in patients with cystic fibrosis: a European Consensus.

Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, Robberecht E, Döring G.

J Cyst Fibros. 2002 Jun;1(2):51-75. Review.

42.

[Expression of the cystic fibrosis gene in the lungs].

Heijerman HG, de Jonge HR.

Ned Tijdschr Geneeskd. 2004 Apr 24;148(17):816-9. Review. Dutch.

PMID:
15141646
43.

To the editor: adverse effects of ceftazidime treatment.

Döring G, Heijerman HG.

Pediatr Pulmonol. 2002 Dec;34(6):496-7. No abstract available.

PMID:
12422350
44.

Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients.

Le Brun PP, de Boer AH, Mannes GP, de Fraîture DM, Brimicombe RW, Touw DJ, Vinks AA, Frijlink HW, Heijerman HG.

Eur J Pharm Biopharm. 2002 Jul;54(1):25-32.

PMID:
12084499
45.
46.
47.

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, Touw DJ.

Eur Respir J. 2000 Oct;16(4):749-67. Review.

48.

A review of the technical aspects of drug nebulization.

Le Brun PP, de Boer AH, Heijerman HG, Frijlink HW.

Pharm World Sci. 2000 Jun;22(3):75-81. Review.

PMID:
11028259
49.

Can tobramycin inhalation be improved with a jet nebulizer?

Le Brun PP, Vinks AA, Touw DJ, Hekelaar N, Mannes GP, Brimicombe RW, Frijlink EH, Heijerman HG.

Ther Drug Monit. 1999 Dec;21(6):618-24.

PMID:
10604822
50.

Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer.

Le Brun PP, de Boer AH, Gjaltema D, Hagedoorn P, Heijerman HG, Frijlink HW.

Int J Pharm. 1999 Nov 5;189(2):215-25.

PMID:
10536250

Supplemental Content

Loading ...
Support Center